Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. reduced its position in shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) by 0.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,104,698 shares of the biotechnology company’s stock after selling 5,514 shares during the period. Vanguard Group Inc. owned 3.82% of Aeglea Bio Therapeutics worth $7,567,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in Aeglea Bio Therapeutics by 24.4% in the 2nd quarter. BlackRock Inc. now owns 1,854,713 shares of the biotechnology company’s stock valued at $12,704,000 after purchasing an additional 364,321 shares in the last quarter. Aisling Capital Management LP boosted its stake in Aeglea Bio Therapeutics by 5.8% in the 2nd quarter. Aisling Capital Management LP now owns 1,291,151 shares of the biotechnology company’s stock valued at $8,844,000 after buying an additional 70,240 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Aeglea Bio Therapeutics by 20.1% in the 2nd quarter. Renaissance Technologies LLC now owns 545,000 shares of the biotechnology company’s stock valued at $3,733,000 after buying an additional 91,200 shares in the last quarter. Northern Trust Corp boosted its stake in Aeglea Bio Therapeutics by 8.6% in the 2nd quarter. Northern Trust Corp now owns 234,621 shares of the biotechnology company’s stock valued at $1,607,000 after buying an additional 18,665 shares in the last quarter. Finally, Fosun International Ltd boosted its stake in Aeglea Bio Therapeutics by 15.9% in the 2nd quarter. Fosun International Ltd now owns 204,148 shares of the biotechnology company’s stock valued at $1,309,000 after buying an additional 28,000 shares in the last quarter. Hedge funds and other institutional investors own 69.34% of the company’s stock.

A number of equities analysts have commented on the company. BidaskClub raised Aeglea Bio Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, September 12th. ValuEngine raised Aeglea Bio Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $14.33.

Shares of AGLE traded down $0.31 on Friday, hitting $7.30. 50,000 shares of the stock traded hands, compared to its average volume of 37,257. The company has a market capitalization of $219.82 million, a PE ratio of -3.43 and a beta of 1.08. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.44 and a current ratio of 8.44. The business has a 50 day simple moving average of $7.91 and a 200 day simple moving average of $7.34. Aeglea Bio Therapeutics Inc has a one year low of $5.99 and a one year high of $9.64.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.07). On average, equities analysts expect that Aeglea Bio Therapeutics Inc will post -2.28 earnings per share for the current year.

Aeglea Bio Therapeutics Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Featured Story: Fundamental Analysis and Individual Investors

Want to see what other hedge funds are holding AGLE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aeglea Bio Therapeutics Inc (NASDAQ:AGLE).

Institutional Ownership by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.